Jump to content
Fall Giveaway Read more... ×
  • Recently Browsing   0 members

    No registered users viewing this page.

EDDIEKIRK

Dronabinol in the treatment of refractory agitation in Alzheimer’s disease

Rate this topic

Recommended Posts

alzheimers-disease.jpg

 

Dronabinol in the treatment of refractory agitation in Alzheimer’s disease

 

Objectives: Primary, to investigate the efficacy of two doses of dronabinol for the treatment of behavioral agitation in community-dwelling patients with Alzheimer�s disease (AD). Secondary, to evaluate two doses of dronabinol in improving the patient�s global functioning and to determine the effects of two doses of dronabinol on the caregiver�s burden, strain (distress), and quality of life.

Design: A phase II, open-label, eight-week study in a total of 54 patients with AD. Twenty-seven patients were randomly assigned to Group 1�dronabinol 2.5 mg bid and 27 to Group 2�dronabinol 5.0 mg bid. The primary efficacy measurement was the Cohen-Mansfield Agitation Inventory (CMAI), a 38-item rating scale that evaluates the prevalence of pathological and disruptive behaviors, rating each on a seven-point scale of frequency ranging from 0 to 6. The secondary efficacy measurements were the Caregiver�s Burden Inventory (CBI), CGI Severity of Alzheimer�s Disease (CGI-S AD), Instrumental Activities of Daily Living scale (IADL), and Mini-Mental State Examination (MMSE).

Results: Significant reductions in CMAI scores were observed at both dronabinol dose levels (2.5: P<0.001, 5.0: P=0.024). The difference between the two groups was not statistically significant. Percent reductions in CMAI scores were statistically significant for both groups (2.5: P<0.001, 5.0: P=0.048). There was a trend toward a decrease in CBI scores, with no statistical difference between treatment groups. There was a trend toward a decrease in CGI-S AD scores in the dronabinol 5.0-mg bid group. There was a trend toward an increase in IADL scores with no difference between groups. There was no difference between groups in MMSE.
Conclusion: The results from the CMAI assessment indicated that dronabinol at both 2.5 mg bid and 5.0 mg bid were effective treatments for behavioral agitation in community-dwelling AD patients. There was not a significant difference between the doses of dronabinol in CMAI scores and most secondary efficacy parameters.

Benefit: Dronabinol was found to be an effective treatment for behavioral agitation in community-dwelling patients with AD.

 

 

Consultant Pharmacists' 34th Annual Meeting, November 12-15, 2003

 

Share this post


Link to post
Share on other sites

×